Catalysts / RCUS
Upcoming FDA decisions and readouts we track for Arcus Biosciences, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Arcus Biosciences (RCUS, listed on Nasdaq). They cover 3 programmes: Casdatifan + zimberelimab (First-line clear cell renal cell carcinoma), Casdatifan + cabozantinib (Second-line clear cell renal cell carcinoma) and Quemliclustat (First-line metastatic pancreatic ductal adenocarcinoma).
First on the list: the Phase 1B readout for Casdatifan + zimberelimab (First-line clear cell renal cell carcinoma), guided by the company to H2 2026. The furthest-out event tracked is H1 2027. By stage, the upcoming rows are 2 Phase 1B readouts and 1 Phase 3 readout.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Arcus Biosciences RCUS · Nasdaq | Casdatifan + zimberelimab | First-line clear cell renal cell carcinoma | H2 2026 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Arcus Biosciences RCUS · Nasdaq | Casdatifan + cabozantinib | Second-line clear cell renal cell carcinoma | H2 2026 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Arcus Biosciences RCUS · Nasdaq | Quemliclustat | First-line metastatic pancreatic ductal adenocarcinoma | H1 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList